Morgan Stanley’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-119,925
| Closed | -$222K | – | 7800 |
|
|
2023
Q1 | $222K | Sell |
119,925
-1,538,000
| -93% | -$1.91M | ﹤0.01% | 5667 |
|
|
2022
Q4 | $1.84M | Sell |
1,657,925
-20,523
| -1% | -$29.2K | ﹤0.01% | 4520 |
|
|
2022
Q3 | $3.93M | Buy |
1,678,448
+48,526
| +3% | +$172K | ﹤0.01% | 3892 |
|
|
2022
Q2 | $4.94M | Buy |
1,629,922
+103,634
| +7% | +$504K | ﹤0.01% | 3783 |
|
|
2022
Q1 | $10.4M | Buy |
1,526,288
+1,490,895
| +4,212% | +$10.6M | ﹤0.01% | 2867 |
|
|
2021
Q4 | $295K | Buy |
35,393
+11,688
| +49% | +$96.3K | ﹤0.01% | 5852 |
|
|
2021
Q3 | $175K | Sell |
23,705
-67,026
| -74% | -$415K | ﹤0.01% | 6071 |
|
|
2021
Q2 | $617K | Buy |
90,731
+73,775
| +435% | +$613K | ﹤0.01% | 5391 |
|
|
2021
Q1 | $174K | Sell |
16,956
-17,773
| -51% | -$195K | ﹤0.01% | 5738 |
|
|
2020
Q4 | $243K | Buy |
34,729
+730
| +2% | +$5.68K | ﹤0.01% | 5495 |
|
|
2020
Q3 | $278K | Buy |
33,999
+9,671
| +40% | +$60K | ﹤0.01% | 4937 |
|
|
2020
Q2 | $168K | Sell |
24,328
-19,930
| -45% | -$108K | ﹤0.01% | 5157 |
|
|
2020
Q1 | $210K | Sell |
44,258
-3,102
| -7% | -$17.9K | ﹤0.01% | 4844 |
|
|
2019
Q4 | $414K | Buy |
47,360
+1,627
| +4% | +$8.79K | ﹤0.01% | 5039 |
|
|
2019
Q3 | $152K | Buy |
45,733
+31,083
| +212% | +$124K | ﹤0.01% | 5273 |
|
|
2019
Q2 | $72K | Sell |
14,650
-1,512
| -9% | -$8.03K | ﹤0.01% | 5465 |
|
|
2019
Q1 | $101K | Sell |
16,162
-103,594
| -87% | -$500K | ﹤0.01% | 5387 |
|
|
2018
Q4 | $403K | Buy |
119,756
+71,003
| +146% | +$332K | ﹤0.01% | 4925 |
|
|
2018
Q3 | $317K | Sell |
48,753
-70,772
| -59% | -$526K | ﹤0.01% | 5241 |
|
|
2018
Q2 | $915K | Buy |
119,525
+81,518
| +214% | +$1.18M | ﹤0.01% | 4682 |
|
|
2018
Q1 | $849K | Sell |
38,007
-9,683
| -20% | -$215K | ﹤0.01% | 4658 |
|
|
2017
Q4 | $607K | Sell |
47,690
-48,231
| -50% | -$709K | ﹤0.01% | 4862 |
|
|
2017
Q3 | $1.49M | Buy |
95,921
+83,561
| +676% | +$1.18M | ﹤0.01% | 4138 |
|
|
2017
Q2 | $174K | Sell |
12,360
-249
| -2% | -$5.33K | ﹤0.01% | 5405 |
|
|
2017
Q1 | $278K | Buy |
+12,609
| New | +$267K | ﹤0.01% | 5157 |
|
Other funds holding JNCE
Morgan Stanley's JNCE Position: Q2 2023 in Review
Morgan Stanley sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 119,925 shares — an estimated $222K sold.
Morgan Stanley first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $10.4M in Q1 2022. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Morgan Stanley reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 119,925 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $222K.
- Morgan Stanley first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Morgan Stanley's Jounce Therapeutics, Inc. Common Stock position peaked at $10.4M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.